Related Experiment Video
Updated: Jan 19, 2026

Oral Combinational Antiretroviral Therapy to Treat HIV-1 Infection in a Humanized Mouse Model
Plasmablastic lymphoma achieving sustained remission with antiretroviral therapy alone
Suheil Albert Atallah-Yunes1, Dermot Murphy1, Romany Abdelmalak2
1Department of Medicine, University of Massachusetts Medical School-Baystate Medical Center, Springfield, Massachusetts.
Abstract:
Despite advances in the treatment of most human immunodeficiency virus (HIV)-related lymphomas, the outcomes for patients with HIV-related plasmablastic lymphoma (PBL) remain poor. While studies have shown an increased survival for patients with most kinds of HIV-related lymphomas since the introduction of highly active antiretroviral therapy (HAART), the impact of HAART on survival in patients with HIV-related PBL is unclear, mainly because the condition is rare and the number of published studies is small. Few case reports have shown regression of PBL after initiation of HAART, however, usually followed by recurrence of PBL or achieved with a need for chemotherapy. We report the first case of PBL in a 38-year-old man with newly diagnosed HIV who achieved sustained remission after the initiation of HAART alone and who remains in remission seven years after diagnosis, without a need for chemotherapy or radiation. We illustrate the importance of initiating HAART therapy under the supervision of infectious disease specialists as soon as the PBL is diagnosed until future studies provide clear evidence in the management of HIV-related PBL.
Related Concept Videos
04:19Oral Combinational Antiretroviral Therapy to Treat HIV-1 Infection in a Humanized Mouse Model
Sustainable Development
18:46Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
17:59Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
10:52Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
08:53Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

